INNOHEP
LEO
Identification
- Active ingredient (INN)
- TINZAPARINE SODIQUE
- Internal code
- 12 B 080
- Country of Origin
- France
- Pharmaceutical form
- SC Injectable Solution (Pre-filled Syringe)
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/02 sering. prerempl. de 0.9ml et b/10 sering. prerempl. de 0.9ml(avec système de securite d'aiguille)
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
Treatment of venous thrombosis and thromboembolic disease including deep venous thrombosis and pulmonary embolism in adults.
For some patients with pulmonary embolism (e.g. those with severe hemodynamic instability) alternative treatment, such as surgery or thrombolysis, may be indicated.
Prolonged treatment of venous thromboembolic disease and prevention of recurrence in adult patients with active cancer.
Associated Conditions
Hemorrhagic disorders
Caution is recommended when d-administration of d-innohep to patients at risk of haemorrhagic disorders.
For patients at risk of major haemorrhage, Combination with medicinal products affecting platelet function or coagulation system should be avoided or closely monitored.
Innohep intramuscular injections should not be injected Intramuscular due to risk of haemorrhagic disorders.
Taking into account the risk of d-haemothematoma, concomitant intramuscular injections should also be avoided.
Heparin-induced thrombocytopenia
A platelet count should be performed before treatment start and repeated regularly thereafter taking into account the risk of thrombocytopenia of immunological origin, absorbetic disorder, absorbetic disorder, absorbetic disorder, absorbetic disorder, absorbetic disorder, absorbetic disorder, absorbetic disorder, absorbetic disorder, absorbobsorbsorbobsorbsorbsorbsor.
Mechanism of Action
Aggregate absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) absorbing agent(s) abing agent(s) abing agent(s) abing agent(s) a.
Adverse Effects
The most commonly reported adverse reactions are: 1st (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal) (abnormal (abnormal) (abnormal) (abnormal) (abnormal) (abnormal (abnormal) (abnormal) (abnormal).